Back to results
US 2024/0200137 A1Published application
Method for the prognosis and/or diagnosis of a disease based on a sample of adipose tissue, and a kit for said method
AssigneeLipozyt Marker Ug
InventorsHelge Wilhelm THIES, Markus KLEMKE
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for the prognosis of adiposity and the prognosis and/or diagnosis of a disease selected from the group consisting of diabetes, cardiovascular diseases and metabolic syndrome
Claims6
A method of determining adipose tissue composition with respect to a proportion of pre-adipocytes and a proportion of mature insulin-sensitive adipocytes in adipose tissue of an individual and assessing risk of developing type II diabetes mellitus comprising the steps of:
- determining a mean of expression of high mobility group AT-hook 2 (HMGA2) and peroxisome proliferator-activated receptor gamma (PPAR-gamma) in adipose tissue of a group of test subjects having type II diabetes mellitus comprising the steps of
- a) puncturing the subcutaneous abdominal adipose tissue of each test subject of the group of test subjects having type II diabetes mellitus to obtain a sample of adipose tissue from the test subject,
- b) extracting nucleic acid from the adipose tissue sample, wherein the sample mass is ≤50 mg and wherein the nucleic acid is RNA;
- c) denaturing the RNA,
- d) reverse transcribing the denatured RNA into cDNA,
- e) pre-amplifying the cDNA, and
- f) measuring gene expression level of HMGA2 via polymerase chain reaction (PCR);
- g) measuring gene expression level of PPAR-gamma via PCR;
- h) calculating the mean of expression of HMGA2 and PPAR-gamma in adipose tissue of the group of test subjects having type II diabetes mellitus;
- obtaining a gene expression profile of HMGA2 and PPAR-gamma in adipose tissue of the individual comprising the steps of:
- a) puncturing the subcutaneous abdominal adipose tissue of the individual having type II diabetes mellitus to obtain a sample of adipose tissue from the individual,
- b) extracting nucleic acid from the adipose tissue sample, wherein the sample mass is <50 mg and wherein the nucleic acid is RNA;
- c) denaturing the RNA,
- d) reverse transcribing the denatured RNA into cDNA,
- e) pre-amplifying the cDNA, and
- f) measuring gene expression level of HMGA2 via polymerase chain reaction (PCR);
- g) measuring gene expression level of PPAR-gamma via PCR;
- h) constructing the gene expression profile of HMGA2 and PPAR-gamma in adipose tissue of the individual from deviation of mean of expression of from the mean of expression of HMGA2 and PPAR-gamma in the test group;
- wherein the adipose tissue of the individual has a high proportion of pre-adipocytes and a low proportion of mature insulin-sensitive adipocytes if deviation of mean expression of HMGA2 from the mean of expression of HMGA2 in the test group is between 0.375 and 1.344 and the deviation of mean expression of PPAR-gamma in the test group is between −0.197 and 0.049;
- wherein the high proportion of pre-adipocytes and a low proportion of mature insulin-sensitive adipocytes in the adipose tissue of the individual indicates an elevated risk of developing type II diabetes mellitus;
- wherein if the adipose tissue of the individual has high proportion of pre-adipocytes and low proportion of mature insulin-sensitive adipocytes, the method further comprises the step of detecting type II diabetes mellitus risk factors of hypertension and/or elevated blood glucose levels comprising measuring blood pressure and/or blood glucose levels.
18 more elements
Dependencies are inferred from the claim text.